10x Genomics price target raised to $13 from $12 at BofA

BofA analyst Michael Ryskin raised the firm’s price target on 10x Genomics (TXG) to $13 from $12 and keeps a Neutral rating on the shares. The firm is updating its price targets for stocks under its coverage in the Life Sciences & Diagnostic Tools, LSTs, sector, the analyst tells investors. The firm notes LSTs remain under pressure as uncertainty persists with the macro environment and U.S. government policies. Recent weeks, however, have seen some signs of improvement as tariff concerns have cools slightly, the firm adds.